CTD Holdings, Inc. companies provide Trappsol® brand cyclodextrins and Aquaplex® brand cyclodextrin complexes to researchers, R&D labs and industrial users in the medical, pharmaceutical, food, and nutritional industries. The symbol CTDH and trades on the OTCQB.

1. OTCQB:CTDH
Overview
CTD Holdings, Inc. owns and acquires companies
that develop, market, (and/or sell) products
containing cyclodextrins (CDs). Cyclodextrins
are rings of glucose molecules that bring oil and
water together for applications requiring oil and
water to work together seamlessly. Cyclodextrins
can make existing consumer products “new and
improved” by greatly enhancing the bio availability
of vitamins or minerals and other characteristics.
There are a myriad of commercial applications for
this supra-molecular phenomenon including areas
of agriculture, analytical chemistry, biotechnology,
cosmetics, diagnostics, electronics, foodstuffs,
pharmaceuticals, and the remediation of toxic waste.
Over the last 20 years, CTD has established itself
as a leading player in the marketing and sale of
cyclodextrin chemistries. In 2010, the Company
purchased a new plant in which to house its high
volume pulse dryer (PD) with which it can manufacture
CD complexes in commercial quantities, solving a
major industrial supply challenge and transforming
the Company into a high value, high volume
Quick Facts & Key Ratios
manufacturer. 12-Month Trading Price High $.20
12-Month Trading Price Low $.03
CTD Holdings Inc. Closing Price 10-28-2011 $.13
(United States)
Shares Outstanding 8-11-2011 35,515,295
Float 8-11-2011 14,415,396
CTD, Inc.
NanoSonic, Sphingo Ferrazo Market Capitalization $4,616,989
Products Biotechnology, Inc. Environmental
Enterprise Value $5,430,468
Last Quarter Revenue $369,000
TTM Revenue $1,094,000
Current Assets (Most Recent 10Q or 10K) $452,205
Current Liabilities (Most Recent 10Q or 10K) $226,750
Current Ratio (Most Recent 10Q or 10K) 1.99 x
Total Assets (Most Recent 10Q or 10K) $2,385,382
Total Liabilities (Most Recent 10Q or 10K) $955,383
Shareholder Equity (Most Recent 10Q or 10K) $1,429,999

2. Why Consider Investing in CTD Holdings
• Management Team are experts in the cyclodextrin market.
• Strong Capital structure, Small Float, Management has lots of skin in
the game.
• CTD recently completed its new manufacturing plant, allowing it to
produce bulk (commercial) amounts of cyclodextrin compounds.
• Closed on Credit Facility Package with SunState Federal Credit Union
in March 2011. It consists of a $325,000 term loan with a $100,000
revolving line of credit.
• Owns a 40 acre farm that is for sale. When sold it will pay off the loan
with SunState Federal Credit Union Immediately.
• World’s only Cyclodextrin Active Pharmaceutical Ingredient (API)
• Orphan Drug Designation, used under Investigational New Drug (IND)
• On the EPA National Contingency Plan List- Approved Products
• cGMP Manufacturing of Food & Pharmaceutical Grades
The Niemann Pick Type C Opportunity
At the end of 2008, one of CTD Holdings’ customers provided one of its products in
an effort to treat a set of twins in the U.S. who were diagnosed with Niemann Pick C
(“NPC”). NPC is also called Childhood Alzheimer’s. It is a fatal disease caused by a
genetic defect that prevents proper handling of cholesterol in the body’s cells. Harmful
amounts of cholesterol accumulate in the spleen, liver, lungs, bone marrow, and
brain. This excess of cholesterol causes progressive neurological deterioration with
symptoms including dementia, seizures, ataxia and cataplexy. The patient’s treatment
with Hydroxy-propyl-beta-cylcodextrin (HPBCD) (now called Trappsol Cyclo™) proved
to provide an ameliorative benefit.
On May 17, 2010, the FDA granted orphan drug status for Trappsol Cyclo™ for the
treatment of Niemann Pick Type C (NPC) disease to this customer. Under the Orphan
Drug Act, companies that develop a drug for a disorder affecting fewer than 200,000
people in the United States may seek designation as an orphan drug and, if such
application is approved, they have the ability to sell it without competition for seven
years, and may get clinical trial tax incentives.
Additional Information
CTD Holdings, Inc.
14120 NW 126th Terrace
Alachua, FL 32615
(386) 418-8060
www.ctd-holdings.com
The WSR Group
3557 SW Corporate Parkway
Palm City, FL 34990
(772) 219-7525
Sean Marconi
smarconi@theWSRgroup.com
Important Note: This profile may contain forward-looking statements, particularly as related to pro forma financial statements, earnings estimates and business expectations, within the meaning of Section 27A of
the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Any statements that express or involve discussions with respect
to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward looking statements.” Forward look-
ing statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially
from those presently anticipated. These forward-looking statements are only made as of the date of their release and CTD Holdings, Inc. does not undertake any obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.